MENU

Fox Chase Cancer Center Hosts Teleconference at the 2019 CGA Annual Meeting to Highlight New Advances in Genetics and Gastrointestinal Cancer

October 28, 2019

The teleconference will take place on November 4, 2019, from 2:30 – 3:30 PM ET. “We are very excited to highlight these exciting studies related to genetic risk of gastrointestinal cancers,” said Dr. Hall. “We look forward to future research in this important area.”The teleconference will take place on November 4, 2019, from 2:30 – 3:30 PM ET. “We are very excited to highlight these exciting studies related to genetic risk of gastrointestinal cancers,” said Dr. Hall. “We look forward to future research in this important area.”SALT LAKE CITY (October 28, 2019) – Michael J Hall, MD, MS, chair of the Department of Clinical Genetics at Fox Chase Cancer Center, will host a teleconference at the 2019 Collaborative Group of the Americas on Inherited Gastrointestinal Cancers (CGA-IGC) Annual Meeting to highlight new advances in gastrointestinal cancer genetics.

The teleconference will take place on November 4, 2019, from 2:30 – 3:30 PM ET and is open to members of the news media.

To dial in, please click on the following link:
https://zoom.us/meeting/register/8cc92e2298e84839cde7dc3c8da9331e

“We are very excited to highlight these exciting studies related to genetic risk of gastrointestinal cancers,” said Hall. “We look forward to future research in this important area.”

News topics include:

Hundreds will gather to learn about news at the 2019 CGA Annual Meeting being held November 3-5, 2019, in Salt Lake City. Hall is the 2019 President of the CGA-IGC.

The CGA-IGC formed in 1995 to improve understanding of the basic science of inherited colorectal and other gastrointestinal cancers and the clinical management of affected families. Its focus is supporting and promoting clinical practice and research related to hereditary gastrointestinal cancers, including clinical research (surgical, gastroenterology, pathology, genetic counseling, oncology, and prevention research) and research in basic science, behavioral science, and health services research. Areas of specific interest include hereditary colorectal cancer syndromes such as familial adenomatous polyposis/FAP juvenile polyposis/JPS, and serrated polyposis, as well as hereditary pancreatic cancer, hereditary gastric cancer, hepatobiliary cancers, and syndromes that include many different types of cancer risks like Lynch syndrome.

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase